Following on from information provided to NICE by the company in April 2019, the appraisal of Chronic Lymphocytic Leukaemia (normal, relapsed or refractory, second line) - Ublituximab + ibrutinib was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019, the appraisal of Chronic Lymphocytic Leukaemia (normal, relapsed or refractory, second line) - Ublituximab + ibrutinib was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 February 2020 | Suspended. Topic suspended |
| 28 February 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of ublituximab in combination with ibrutinib for previously treated high-risk chronic lymphocytic leukaemia. The company have advised that they will not be pursuing a Marketing Authorisation Application for ublituximab in combination with ibrutinib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual